Role of radical surgical treatment in patients with soft tissue sarcomas invading bone

To analyze the overall survival, mid-term, and long-term outcomes, as well as the complication structure in a group of patients after endoprosthetic replacement for soft tissue sarcomas infiltrating bone, the treatment results of 19 patients who underwent 24 primary and repeated surgeries from May 2004 to November 2021 were analyzed. The average follow-up period was 132.5 months. The average age at the time of endoprosthetic replacement was 47.7 ± 15.3 years. It was shown that the event-free survival of the operated patients after 3 years was 61.5 ± 11.5 %, after 5 years – 54.7 % ± 12.1 %, and remained at the same level after 10 years. The average time to tumor recurrence was 11 months, lung metastasis occurred at 96 months, and both recurrence and metastases were detected on average within 2 months. The overall survival of patients with soft tissue sarcomas through 3 years was 93.3 ± 6.4 %, through 5 years – 80.0 ± 10.3 %, and through 10 years – 65.5 ± 12.6 %. Across the entire group of respondents, disease progression was observed in 42.1 % of cases, tumor recurrence in 31.6 %; metastases (to the lungs) in 5.3 %; recurrence of the disease and metastases in 5.3 %. These data indicate that endoprosthetic replacement as a component of combined organ-preserving treatment for patients with soft tissue sarcomas infiltrating bone is an effective treatment method for improving the quality of life of patients, despite certain risks of disease recurrence, metastasis, and complications.